2-Methyl-3-(pyrrolidin-1-yl)propan-1-amine | 893644-54-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-Methyl-3-(pyrrolidin-1-yl)propan-1-amine
• 英文别名: 2-methyl-3-pyrrolidin-1-ylpropan-1-amine
• CAS: 893644-54-7
• 化学式: C₈H₁₈N₂
• mdl: MFCD08700481
• 分子量: 142.24
• InChiKey: UOJULWGNCNKVHI-UHFFFAOYSA-N

物化性质

• 沸点：
  200.8±8.0 °C(Predicted)
• 密度：
  0.921±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Efficient stereoconservative syntheses of 1-substituted (S)- and (R)-2-aminomethylpyrrolidines and intermediates therein
  申请人：ASTRA LAKEMEDEL AKTIEBOLAG

  公开号：EP0253785A1

  公开（公告）日：1988-01-20

  Stereoconservative method for preparation of an (R)- or (S)-isomer of the compound of the formula I with at least 95% optical purity wherein R1 is a hydrogen atom, a saturated or unsaturated lower alkyl group, a cycloalkyl group, or a group (CH2)m Ph wherein m is O-3 and Ph is a substituted or unsubstituted phenyl group including I) O,N-dialkylation, directly or stepwise of (R)- or (S)-proline 2) aminolysis 3) reduction to formation of the (R)- or (S)-isomer of the compound of the formula I, and new intermediates II and III in optical active form obtained by the reaction steps above and wherein R2 is defined as R1 above.

  制备光学纯度至少为 95%的式 I 化合物的(R)-或(S)-异构体的立体保守方法 其中 R1 是氢原子、饱和或不饱和低级烷基、环烷基或基团 (CH2)m Ph，其中 m 是 O-3，Ph 是取代或未取代的苯基，包括 I) 直接或逐步对(R)-或(S)-脯氨酸进行 O,N-二烷基化反应 2) 氨解 3) 还原形成式 I 化合物的(R)-或(S)-异构体，以及通过上述反应步骤获得的光学活性形式的新中间体 II 和 III，其中 R2 的定义与上述 R1 相同。
• Composition containing aziridino groups, method of production and use thereof
  申请人：3M Innovative Properties Company

  公开号：EP1865014A1

  公开（公告）日：2007-12-12

  The invention relates to a composition comprising a prepolymer as component (A), wherein the prepolymer comprises aziridino groups and is characterized by an equivalent weight EW1, a crosslinker as component (B), wherein the crosslinker has a structure being different from the structure of the prepolymer and comprises at least three 2-alkylsubstituted aziridino groups and is characterized by an equivalent weight EW2, an initiator as component (C) being able to start curing of the composition, optionally filler(s) as component (D) and optionally additive(s) as component (E), wherein equivalent weight is defined as (molecular mass of the molecule) / (number of aziridino groups present in the molecule) and wherein EW1 > EW2. The invention also relates to the use of the composition for coating, sealing, moulding, adhering, making impressions, producing a dental material.

  本发明涉及一种组合物，该组合物包括作为组分（A）的预聚物，其中预聚物包含氮丙啶基团，其特征在于等效重量 EW1；作为组分（B）的交联剂，其中交联剂的结构与预聚物的结构不同，包含至少三个 2-烷基取代的氮丙啶基团，其特征在于等效重量 EW2、作为成分（C）的引发剂能够启动组合物的固化，作为成分（D）的可选填料和作为成分（E）的可选添加剂，其中等效重量定义为（分子的分子质量）/（分子中存在的氮丙啶基数），其中 EW1 > EW2。 本发明还涉及将该组合物用于涂层、密封、成型、粘合、制模、生产牙科材料。
• Verwendung von N-(Aminoalkyl)-pyrrolidinen als Katalysator für das Polyisocyanatpolyadditionsverfahren und Verfahren zur Herstellung von Polyurethan(harnstoff)en
  申请人：BAYER AG

  公开号：EP0495249B1

  公开（公告）日：1994-07-27
• COMPOSITION CONTAINING AZIRIDINO GROUPS, METHOD OF PRODUCTION AND USE THEREOF
  申请人：3M Innovative Properties Company

  公开号：EP2027185A2

  公开（公告）日：2009-02-25
• IONIZABLE LIPIDOIDS AND THEIR USES
  申请人：Massachusetts Institute of Technology

  公开号：US20200109121A1

  公开（公告）日：2020-04-09

  Provided herein are lipidoid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipidoid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a cell.